Arvinas Presents Late Breaking, Positive Phase 1 Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson's Disease and Movement Disorders®

Core Insights - Arvinas, Inc. announced positive results from two Phase 1 clinical trials for ARV-102, an investigational PROTAC degrader targeting LRRK2, showing well-tolerated safety profiles and significant pharmacodynamic effects in both healthy volunteers and Parkinson's disease patients [1][2][5] Group 1: Clinical Trial Results - ARV-102 was well tolerated in clinical trials, with no discontinuations due to adverse events observed [6] - In healthy volunteers, ARV-102 demonstrated dose-dependent cerebrospinal fluid (CSF) exposure and reduced biomarkers associated with Parkinson's disease after 14 days of treatment [1][6] - In patients with Parkinson's disease, ARV-102 resulted in median reductions of LRRK2 protein of 86% with a 50 mg dose and 97% with a 200 mg dose [6] Group 2: Biomarker and Pharmacodynamic Findings - The treatment led to over 90% reductions of LRRK2 protein in peripheral blood mononuclear cells (PBMCs) and more than 50% reductions in CSF [6] - Significant decreases in lysosomal pathway markers and neuroinflammatory microglial markers were observed in CSF of healthy volunteers treated with ARV-102 [6][9] Group 3: Future Development Plans - Arvinas plans to present initial data from a multiple dose cohort of the Phase 1 clinical trial in patients with Parkinson's disease in 2026 [7] - The company intends to initiate a Phase 1b trial in patients with progressive supranuclear palsy in the first half of 2026, pending data from the multiple dose cohort and investigational new drug clearance [7]